AlphaMadera's AlphaVal page classifies NRC Health as a Stable Earnings Power business and values it using P/Adj-EPS × Normalized Multiple, then compares the result to the current market price to flag NRC as undervalued, fairly valued, or overvalued.

What is NRC Health's fair value?

Fair value for NRC comes from a P/Adj-EPS × Normalized Multiple model -- the approach AlphaVal selected for this company's Stable Earnings Power classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value NRC?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. NRC was classified as Stable Earnings Power and is valued using P/Adj-EPS × Normalized Multiple, built from NRC's most recent reported fundamentals.

NRC - NRC Health

Price: -- -- | CONSENSUS: Buy DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Moderate

Trading 33.1% above fair value

Current Price $20.87

Bear Case $12.54 39.9% downside ($12.54 - $20.87) / $20.87 = -39.9% $1.25 × 10x P/E

Fair Value $15.68 24.9% downside ($15.68 - $20.87) / $20.87 = -24.9% $1.25 × 12x P/E

Bull Case $18.81 9.9% downside ($18.81 - $20.87) / $20.87 = -9.9% $1.25 × 15x P/E

Adjust Assumptions

P/E Multiple

12.5x

Adjusted EPS

1.25$

Key Value Driver

Normalized P/E multiple (12x base case)

Terminal Value % of EV

Implied Market Multiple 16.6x

Market is pricing in (growth)

Plain-Language Summary

Applying a 12x P/E to adjusted EPS of $1.25, the base-case value is $15.68 per share.

Warnings

⚠ The company's reported profits differ from official accounting profits by 141%. Check what costs are being left out of the adjusted number.

⚠ The company pays out 123% of its profits as dividends. That leaves little cushion — the dividend could be cut if business slows down.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples